Prime Medicine, Inc. (PRME) stock
Close on Nov 11, 2026Market cap $779.92MP/E –Yield –
Prime Medicine, Inc. grew revenue 55.3% to $4.63M over fiscal 2025. Free cash flow was -$158.54M. At the latest close the market valued the company at $779.92M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $779.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 19.59
- Dividend yield
- –
- Free cash flow yield
- -20.11%
Fundamentals
- Revenue
- $4.63M
- Net income
- -$176.35M
- EPS, diluted
- -$1.00
- Free cash flow
- -$158.54M
- Book value per share
- $0.05
- Diluted shares
- 178M
Trading
- Next earnings
- Mar 2, 2027 (estimated, before the open)
- Previous close
- $3.90
- Open
- $3.89
- Day's range
- $3.80 – $4.35
- Volume
- 12,846,860
- Average volume (20 days)
- 5,753,668
- Index membership
- Russell 2000 (since Dec 2022), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 2.06
- 52-week range
- $2.67 – $5.91
- RSI (14 days)
- 52.3
- Volatility (1 year)
- 92.8%
- Relative volume
- 3.24×
- WACC
- 15.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PRME | S&P 500 | Difference | PRME per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.8% | -2.4% | +10.2 pts | ||
| 3 months | +31.9% | -1.2% | +33.1 pts | ||
| Year to date | +23.9% | +12.3% | +11.6 pts | ||
| 1 year | +9.7% | +12.4% | −2.8 pts | ||
| 3 years | -36.8% | +78.8% | −115.6 pts | -14.2% | +21.4% |
| 5 years | -78.7% | +75.2% | −153.9 pts | -26.6% | +11.9% |
| 10 years | -77.8% | +311.1% | −388.9 pts | -14.0% | +15.2% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Prime Medicine filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Prime Medicine
Biological Products, (No Diagnostic Substances)
The company is a biotechnology enterprise that develops genetic medicines using prime editing technology to correct pathogenic mutations without generating double-stranded DNA breaks. Its development pipeline encompasses wholly owned in vivo therapies for genetic liver and lung conditions as well as partnered ex vivo cell therapies. Key product candidates include PM577 for Wilson disease, PM647 for alpha-1 antitrypsin deficiency, an airway program for cystic fibrosis, and PM359 for chronic granulomatous disease. Its target beneficiaries are patients with severe genetic disorders, while its commercial counterparties and collaborators include biopharmaceutical corporations such as Bristol-Myers Squibb and non-profit organizations like the Cystic Fibrosis Foundation.
Company profile, executives and historyPrime Medicine stock: common questions
What is Prime Medicine's stock price?
PRME closed at $4.30 on Nov 11, 2026, up 10.26% on the day. Over the past 52 weeks it traded between $2.67 and $5.91.
What is Prime Medicine's market cap?
Prime Medicine was worth $779.92M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PRME's P/E ratio?
Prime Medicine lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.00), so it has no meaningful P/E ratio.
How much revenue does Prime Medicine make?
Prime Medicine reported revenue of $4.63M for fiscal 2025, up 55.3% from a year earlier.
Does Prime Medicine pay a dividend?
No. Prime Medicine has not paid a cash dividend over the last twelve months.
When does Prime Medicine report earnings next?
Prime Medicine is expected to report Q4 FY2026 results on Mar 2, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PRME stock performed over the past year?
Including dividends, PRME returned +9.7% over the past year, against +12.4% for the S&P 500.
How many PRME shares are sold short?
29M shares were sold short at the latest FINRA report, 19.74% of the float, or 4.8 days of average trading volume.
Who are Prime Medicine's competitors?
Companies most similar to Prime Medicine by business, industry and size include OCGN, ALGS, EDIT, TRDA, ELOX.
See a number that looks wrong?